Dr. Shepard appointment last week SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, July 9, 2020 – Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) today announced the appointment of Dr. H. Michael Shepard to its Board of Directors.
Dr. Shepard was a 2019 recipient of the Lasker Award for medical research and public service, conferred for his role in the discovery and development of the drug Herceptin (trastuzumab). The Lasker Awards are regarded as America’s top biomedical research prize, and approximately 90 past recipients have proceeded to win a Nobel Prize. Herceptin treats breast cancer patients with HER2-positive tumours, marking an especially aggressive form of the disease. Over 2 million patients have benefited from this discovery.